Search
Menu
Home
HTB
2021
November
November 2021
Contents
Editorial
HTB: no. 11 – plus HIV and COVID-19 (Nov/Dec 2021)
IAS review on HIV cure research: A global scientific strategy to cure HIV (2021)
Conference reports
18th International European AIDS Conference (EACS 2021)
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
HIV-specific mental health services across the EU
Antiretrovirals
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring
Other news
UK oral history project for young people who were born with HIV
COVID-19: investigational drugs
Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs
Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab
PDFs
HTB: no. 11 – plus HIV and COVID-19 (30 November 2021)
HTB RSS
Early access
Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news
4 May 2025
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025
All early access reports
Current issues
May 2025
April 2025
March 2025
Back issues
Special report
Reduced dosing: a possible crisis response to ART stockouts and closed clinics
5 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate